Atlas FDA

ACCESS HYBRITECH PSA ON THE SYNCHRON LXI 725 SYSTEM

FDA premarket approval P850048/S018 · decided 2003-01-09

Approval details

PMA number
P850048
Supplement
S018
Supplement type
Real-Time Process
Supplement reason
Change Design/Components/Specifications/Material
Trade name
ACCESS HYBRITECH PSA ON THE SYNCHRON LXI 725 SYSTEM
Generic name
PROSTATE-SPECIFIC ANTIGEN (PSA) FOR MANAGEMENT OF PROSTATE CANCERS
Applicant
Beckman Coulter, Inc.
Date received
2002-10-04
Decision date
2003-01-09
Days to decision
97 days
Decision code
APPR
Product code
LTJ
Advisory committee
Immunology
Expedited review
No
Location
Brea, CA
Statement
APPROVAL TO ADD THE ACCESS HYBRITECH PSA ASSAY TO THE SYNCHRON LXI 725 SYSTEM.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Access BNP II (K252169)Beckman Coulter, Inc.2026-03-24
Access anti-HBc IgM (K254059)Beckman Coulter, Inc.2026-03-13
Access anti-HBc Total (K253687)Beckman Coulter, Inc.2026-02-19
Access anti-HAV IgM (K251995)Beckman Coulter, Inc.2026-01-27
Access Rubella IgG (K250588)Beckman Coulter, Inc.2025-11-17
iQ200 Series (K252580)Beckman Coulter, Inc.2025-09-10
Access anti-HAV (K243846)Beckman Coulter, Inc.2025-09-09
MicroScan Dried Gram-Negative MIC/Combo Panels with Cefepime (CPE) (0.12-64 µg/mL) (MicroScan) (K243804)Beckman Coulter, Inc.2025-08-20